| top | |
| GLIOBLASTOMA NEWSLETTER | |
Volume 1, Number 7 - 5 October 2002 |
|
THE REFERENCES FROM THE ARTICLE
"TREATMENT OPTIONS FOR GLIOBLASTOMA AND OTHER GLIOMAS" BY BEN
WILLIAMS
(Last Updated:
September 25, 2002. Source: http://www.virtualtrials.com/williams.cfm
)
Part 1 - Reference Numbers from 1 to 20 (Glioblastoma Newsletter, 2 Oct. 2002, Vol. 1, No. 6)
Part 2 - Reference Numbers from 21 to 40 (To be issued later)
Part 3 - Reference Numbers from 41 to 60 (This issue).
Couldwell
WT, Weiss MH, DeGiorgio CM, Weiner LP, Hinton DR, Ehresmann GR, Conti PS,
Apuzzo ML.
Clinical and
radiographic response in a minority of patients with recurrent malignant gliomas
treated with high-dose tamoxifen
Neurosurgery 1993 Mar;32(3):485-9 (Abstract)
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8384328&dopt=Abstract
Couldwell
WT, Hinton DR, Surnock AA, DeGiorgio CM, Weiner LP, Apuzzo ML, Masri L, Law
RE, Weiss MH
Treatment
of recurrent malignant gliomas with chronic oral high-dose tamoxifen
Clin Cancer Res 1996 Apr;2(4):619-22 (Abstract)
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9816211&dopt=Abstract
Mastronardi
L, Puzzilli F, Couldwell WT, Farah JO, Lunardi P.
Tamoxifen
and carboplatin combinational treatment of high-grade gliomas. Results of a
clinical trial on newly diagnosed patients
J
Neurooncol 1998 May;38(1):59-68 (Abstract)
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9540058&dopt=Abstract
Napolitano
M, Keime-Guibert F, Monjour A, Lafitte C, Ameri A, Cornu P, Broet
P, Delattre JY
Treatment
of supratentorial glioblastoma multiforme with radiotherapy and a combination of
BCNU and tamoxifen: a phase II study
J Neurooncol 1999;45(3):229-35 (Abstract)
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10845393&dopt=Abstract
Preul
MC, Caramanos Z, Villemure JG, Shenouda G, LeBlanc R, Langleben A, Arnold DL
Using
proton magnetic resonance spectroscopic imaging to predict in vivo the response
of recurrent malignant gliomas to tamoxifen chemotherapy
Neurosurgery 2000 Feb;46(2):306-18 (Abstract)
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10690719&dopt=Abstract
Lav
Goyal, Aleck Hercbergs, John Suh, Robert Fine, Bruce Cohen, David Peerboom,
Glen Stevens, Manjula Gupta, Sethu Reddy, Chandana Reddy, Paul Elson, Gene
Barnett
High-Dose
Tamoxifen and Thyroid Suppression in Recurrent Malignant Glioma Patients
ASCO
Proceedings, 2000 Annual Meeting, Abstract No. 655
Source: http://www.asco.org/asco/ascoMainConstructor
/1,47468,_12|002326|00_29|00A|00_18|002000|00_19|00100154,00.asp
Yung WK,
Kyritsis AP, Gleason MJ, Levin VA
Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid
Clin Cancer Res 1996 Dec;2(12):1931-5 (Abstract)
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9816151&dopt=Abstract
Fine
HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black
PM, Kaplan R, Pluda JM, Yung WK
Phase II trial of
the antiangiogenic agent thalidomide in patients with recurrent high-grade
gliomas
J Clin
Oncol 2000 Feb;18(4):708-15 (Abstract)
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10673511&dopt=Abstract
Marx GM,
Pavlakis N, McCowatt S, Boyle FM, Levi JA, Bell DR, Cook R, Biggs M, Little N,
Wheeler HR
Phase II study of thalidomide in the treatment of
recurrent glioblastoma multiforme
J Neurooncol 2001 Aug;54(1):31-8 (Abstract)
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11763420&dopt=Abstract
Jo
Glass, Gruber Michael , Anit Nirenberg
Phase I/II Study of Carboplatin and Thalidomide in
Recurrent Glioblastoma Multiforme
ASCO
Proceedings, 1999 Annual Meeting, Abstract
No.
551
Source: http://www.asco.org/asco/ascoMainConstructor
/1,47468,_12|002326|00_29|00A|00_18|001999|00_19|0014804,00.asp
Kilic T, Alberta JA, Zdunek PR, Acar M, Iannarelli P, O'Reilly T, Buchdunger
E, Black PM, Stiles CD
Intracranial
inhibition of platelet-derived growth factor-mediated glioblastoma cell growth
by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class
Cancer Res 2000 Sep 15;60(18):5143-50 (Abstract,
Full Text)
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11016641&dopt=Abstract
Free
Full Text article at: http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?
http://cancerres.aacrjournals.org/cgi/pmidlookup?view=full&pmid=11016641
Patrick
Y Wen, W K Yung, Kenneth Hess, Sandra Silberman, Michael Hayes, David
Schiff, Frank Lieberman, Timothy F Cloughesy, Lisa M DeAngelis, Susan M Chang,
Larry Junck, Howard A Fine, Karen Fink, H I Robins, Jeffrey J Raizer, Lauren E
Abrey, Minesh P Mehta, Elizabeth A Maher, Peter M Black, John Kuhn, Renaud
Capdeville, Richard S Kaplan, Anthony Murgo, Charles Stiles, Michael D Prados
Phase I study of STI571
(Gleevec) for patients with
recurrent malignant gliomas and meningiomas (NABTC 99-08)
ASCO
Proceedings, 2002 Annual Meeting, Abstract No. 288
Source: http://www.asco.org/asco/ascoMainConstructor
/1,47468,_12|002326|00_28|002|00_29|00A|00_18|002002|00_19|00288,00.asp
Jones
MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, Tarnawski AS
Inhibition of
angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms
and implications for cancer growth and ulcer healing
Nat
Med 1999 Dec;5(12):1418-23 (Abstract)
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10581086&dopt=Abstract
Gately
S
The
contributions of cyclooxygenase-2 to tumor angiogenesis
Cancer Metastasis Rev 2000;19(1-2):19-27 (Abstract)
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11191059&dopt=Abstract
Alshafie
GA, Abou-Issa HM, Seibert K, Harris RE
Chemotherapeutic
evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor
model
Oncol
Rep 2000 Nov-Dec;7(6):1377-81 (Abstract)
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11032948&dopt=Abstract
Nasser
K Altorki, Roger S Keresztes, Jeffrey L Port, Douglas B Flieder, Cathy A
Ferrara, Mark W Pasmantier, Daniel M Libby, David Yankelevitz, Andrew J
Dannenberg
Celecoxib (Celebrex), a selective COX-2 inhibitor,
enhances the response to preoperative paclitaxel/carboplatin in early stage
non-small cell lung cancer
ASCO
Proceedings, 2002 Annual Meeting, Abstract No. 101
Source: http://www.asco.org/asco/ascoMainConstructor
/1,47468,_12|002326|00_29|00A|00_18|002002|00_19|00101,00.asp
Lissoni P, Rovelli F, Malugani F, Bucovec R, Conti A,
Maestroni GJ
Anti-angiogenic
activity of melatonin in advanced cancer patients
Neuroendocrinol
Lett 2001;22(1):45-7 (Abstract)
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11335879&dopt=Abstract
Lissoni P, Meregalli S, Nosetto
L, Barni S, Tancini G, Fossati V, Maestroni G.
Increased survival time
in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus
melatonin compared to radiotherapy alone
Oncology
1996 Jan-Feb;53(1):43-6 (Abstract)
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8570130&dopt=Abstract
OTHER
SUGGESTED REFERENCES ON
TAMOXIFEN (Vertosick, 1992)
AND PATHOGENESIS (Verheul, 1998)
Vertosick
FT Jr, Selker RG, Pollack IF, Arena V
The treatment of intracranial malignant gliomas
using orally administered tamoxifen therapy: preliminary results in a series of
"failed" patients
Neurosurgery
1992 Jun;30(6):897-902 (Abstract); discussion 902-3
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1377370&dopt=Abstract
Verheul
HM, Pinedo HM
Tumor Growth: A Putative Role for
Platelets?
Oncologist
1998;3(2):II (Abstract, Full Text)
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10388096&dopt=Abstract
Free Full Text article at: www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?
http://theoncologist.alphamedpress.org/cgi/pmidlookup?view=full&pmid=10388096